Tumor Growth Suppression Using a Combination of Taxol-based Therapy and GSK3 Inhibition in Non-small Cell Lung Cancer

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2019 Apr 11

PMID 30969984

Citations 14

Authors

Linda OFlaherty

Steven D Shnyder

Patricia A Cooper

Stephen J Cross

James G Wakefield

Olivier E Pardo

Michael J Seckl

Jeremy M Tavare

Affiliations

Soon will be listed here.

Abstract

Glycogen synthase kinase-3 (GSK3) is over-expressed and hyperactivated in non-small cell lung carcinoma (NSCLC) and plays a role in ensuring the correct alignment of chromosomes on the metaphase plate during mitosis through regulation of microtubule stability. This makes the enzyme an attractive target for cancer therapy. We examined the effects of a selective cell-permeant GSK3 inhibitor (CHIR99021), used alone or in combination with paclitaxel, using an in vitro cell growth assay, a quantitative chromosome alignment assay, and a tumor xenograft model. CHIR99021 inhibits the growth of human H1975 and H1299 NSCLC cell lines in a synergistic manner with paclitaxel. CHIR99021 and paclitaxel promoted a synergistic defect in chromosomal alignment when compared to each compound administered as monotherapy. Furthermore, we corroborated our in vitro findings in a mouse tumor xenograft model. Our results demonstrate that a GSK3 inhibitor and paclitaxel act synergistically to inhibit the growth of NSCLC cells in vitro and in vivo via a mechanism that may involve converging modes of action on microtubule spindle stability and thus chromosomal alignment during metaphase. Our findings provide novel support for the use of the GSK3 inhibitor, CHIR99021, alongside taxol-based chemotherapy in the treatment of human lung cancer.

Citing Articles

Inhibition of GSK3β is synthetic lethal with FHIT loss in lung cancer by blocking homologous recombination repair.

Tao S, Pu Y, Yang E, Ren G, Shi C, Chen L Exp Mol Med. 2025; 57(1):167-183.

PMID: 39762409 PMC: 11799392. DOI: 10.1038/s12276-024-01374-0.

GSK3B inhibition reduced cervical cancer cell proliferation and migration by modulating the PI3K/Akt signaling pathway and epithelial-to-mesenchymal transition.

Zheng Y, Yang Y, Zhu W, Liu R, Liu A, Zhang R Braz J Med Biol Res. 2024; 57:e13796.

PMID: 39166606 PMC: 11338547. DOI: 10.1590/1414-431X2024e13796.

Pharmacological Modulation of the Cytosolic Oscillator Affects Glioblastoma Cell Biology.

Wagner P, Fornasier S, Guido M Cell Mol Neurobiol. 2024; 44(1):51.

PMID: 38907776 PMC: 11193694. DOI: 10.1007/s10571-024-01485-2.

Concurrent targeting of GSK3 and MEK as a therapeutic strategy to treat pancreatic ductal adenocarcinoma.

Fukuda J, Kosuge S, Satoh Y, Sekiya S, Yamamura R, Ooshio T Cancer Sci. 2024; 115(4):1333-1345.

PMID: 38320747 PMC: 11007052. DOI: 10.1111/cas.16100.

Biphasic function of GSK3β in gefitinib‑resistant NSCLC with or without EGFR mutations.

Li J, Wu X, Ji X, He C, Xu S, Xu X Exp Ther Med. 2023; 26(4):488.

PMID: 37745038 PMC: 10515113. DOI: 10.3892/etm.2023.12187.

References

Kotliarova S, Pastorino S, Kovell L, Kotliarov Y, Song H, Zhang W . Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res. 2008; 68(16):6643-51. PMC: 2585745. DOI: 10.1158/0008-5472.CAN-08-0850. View

Owonikoko T, Ramalingam S, Kanterewicz B, Balius T, Belani C, Hershberger P . Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. Int J Cancer. 2009; 126(3):743-55. PMC: 2795066. DOI: 10.1002/ijc.24759. View

Schiff P, Horwitz S . Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A. 1980; 77(3):1561-5. PMC: 348536. DOI: 10.1073/pnas.77.3.1561. View

Grassilli E, Narloch R, Federzoni E, Ianzano L, Pisano F, Giovannoni R . Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy. Clin Cancer Res. 2013; 19(14):3820-31. DOI: 10.1158/1078-0432.CCR-12-3289. View

Hu Y, Gu X, Li R, Luo Q, Xu Y . Glycogen synthase kinase-3β inhibition induces nuclear factor-κB-mediated apoptosis in pediatric acute lymphocyte leukemia cells. J Exp Clin Cancer Res. 2010; 29:154. PMC: 3002327. DOI: 10.1186/1756-9966-29-154. View

Zheng H, Saito H, Masuda S, Yang X, Takano Y . Phosphorylated GSK3beta-ser9 and EGFR are good prognostic factors for lung carcinomas. Anticancer Res. 2007; 27(5B):3561-9. View

Belani C . Paclitaxel and docetaxel combinations in non-small cell lung cancer. Chest. 2000; 117(4 Suppl 1):144S-151S. DOI: 10.1378/chest.117.4_suppl_1.144s. View

Li C, Zhang S, Lu Y, Zhang Y, Wang E, Cui Z . The roles of Notch3 on the cell proliferation and apoptosis induced by CHIR99021 in NSCLC cell lines: a functional link between Wnt and Notch signaling pathways. PLoS One. 2013; 8(12):e84659. PMC: 3867546. DOI: 10.1371/journal.pone.0084659. View

Yin Y, Kizer N, Thaker P, Chiappinelli K, Trinkaus K, Goodfellow P . Glycogen synthase kinase 3β inhibition as a therapeutic approach in the treatment of endometrial cancer. Int J Mol Sci. 2013; 14(8):16617-37. PMC: 3759928. DOI: 10.3390/ijms140816617. View

10.

Brognard J, Dennis P . Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. Cell Death Differ. 2002; 9(9):893-904. DOI: 10.1038/sj.cdd.4401054. View

11.

Shimura T . Acquired radioresistance of cancer and the AKT/GSK3β/cyclin D1 overexpression cycle. J Radiat Res. 2011; 52(5):539-44. DOI: 10.1269/jrr.11098. View

12.

Tinevez J, Perry N, Schindelin J, Hoopes G, Reynolds G, Laplantine E . TrackMate: An open and extensible platform for single-particle tracking. Methods. 2016; 115:80-90. DOI: 10.1016/j.ymeth.2016.09.016. View

13.

Gao C, Holscher C, Liu Y, Li L . GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Rev Neurosci. 2012; 23(1):1-11. DOI: 10.1515/rns.2011.061. View

14.

Emamian E . AKT/GSK3 signaling pathway and schizophrenia. Front Mol Neurosci. 2012; 5:33. PMC: 3304298. DOI: 10.3389/fnmol.2012.00033. View

15.

MacKeigan J, Collins T, Ting J . MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem. 2000; 275(50):38953-6. DOI: 10.1074/jbc.C000684200. View

16.

Doble B, Woodgett J . GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci. 2003; 116(Pt 7):1175-86. PMC: 3006448. DOI: 10.1242/jcs.00384. View

17.

Ougolkov A, Fernandez-Zapico M, Savoy D, Urrutia R, Billadeau D . Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res. 2005; 65(6):2076-81. DOI: 10.1158/0008-5472.CAN-04-3642. View

18.

Wang Z, Smith K, Murphy M, Piloto O, Somervaille T, Cleary M . Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature. 2008; 455(7217):1205-9. PMC: 4084721. DOI: 10.1038/nature07284. View

19.

Woodgett J . Physiological roles of glycogen synthase kinase-3: potential as a therapeutic target for diabetes and other disorders. Curr Drug Targets Immune Endocr Metabol Disord. 2003; 3(4):281-90. PMC: 4490889. DOI: 10.2174/1568008033340153. View

20.

Wagman A, Johnson K, Bussiere D . Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr Pharm Des. 2004; 10(10):1105-37. DOI: 10.2174/1381612043452668. View